News

Acerus Pharmaceuticals Corporation announced that it has signed a patent license agreement with the University of Texas at Austin for technology related to the nasal administration of…
Read More...

Modulus Discovery, an early stage global biopharmaceutical company, announced the signing of research data transfer agreement on a specific drug target with Astellas Pharma. Under…
Read More...

Epizyme, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat for the treatment of…
Read More...

Imara, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, announced that the U.S. Food and Drug Administration (FDA) has…
Read More...

AgilVax, Inc., a biotechnology company developing targeted antibody-based therapies for the treatment of various cancers, including metastatic breast cancer (MBC), announced that the…
Read More...

Prestige BioPharma announced that European Medicines Agency (EMA) has validated and accepted for review the Marketing Authorization Application (MAA) for its trastuzumab biosimilar…
Read More...

Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from…
Read More...

Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania (Penn) announced a major expansion to their collaboration with rights to pursue collaborative…
Read More...

Almac Sciences, a member of the Almac Group, announced the appointment of Dr Sheryl Foster to the position of Vice President of Quality, reporting to Managing Director & President,…
Read More...

Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Ranexa (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S. Ranolazine…
Read More...

Eli Lilly and Company announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing…
Read More...

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced innovative access programs for Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with…
Read More...

Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute GVHD in adult and pediatric…
Read More...

Pfizer Inc. announced that a Phase 3 study to assess the use of LYRICA (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized…
Read More...

AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than…
Read More...

GlaxoSmithKline plc announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or…
Read More...

ProBioGen AG announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, Abcuro has developed a new…
Read More...

Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group),…
Read More...